BRAFV600E Inhibitor Radiosensitizes Thyroid Cancer—Letter

We read with great interest the article by Robb and colleagues ([1][1]), wherein they explored the mechanisms of radiosensitizing BRAF V600E–mutated thyroid cancers using the tyrosine kinase inhibitor vemurafenib. The authors describe a mechanism for the increased radioresistance of V600E-mutated